Koichi Oshita Selected Research

amiselimod

1/2019	Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models.
1/2019	Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4+CD45RBhigh T cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Koichi Oshita Research Topics

Disease

2	Arthritis (Polyarthritis) 01/2015 - 12/2013
1	Colitis 01/2019
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2019
1	Lupus Nephritis 01/2019
1	Sclerosis 01/2019
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2019
1	Neoplasms (Cancer) 03/2016
1	Experimental Arthritis 12/2013
1	Rheumatoid Arthritis 12/2013
1	Inflammation (Inflammations) 01/2013

Drug/Important Bio-Agent (IBA)

2	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 01/2019 - 01/2019
2	amiselimodIBA 01/2019 - 01/2019
2	Collagen Type II (Type II Collagen)IBA 01/2015 - 12/2013
2	Interleukin-17 (Interleukin 17)IBA 12/2013 - 01/2013
2	CytokinesIBA 12/2013 - 01/2013
1	Therapeutic UsesIBA 01/2019
1	Sphingosine-1-Phosphate ReceptorsIBA 01/2019
1	Tacrolimus (Prograf)FDA LinkGeneric 01/2019
1	Immunosuppressive Agents (Immunosuppressants)IBA 03/2016
1	InterleukinsIBA 12/2013
1	Interleukin-15 (Interleukin 15)IBA 12/2013
1	Messenger RNA (mRNA)IBA 12/2013

Therapy/Procedure

1	Oral Administration 12/2013